Immunic, Inc. (NASDAQ: IMUX) Executes Reverse Stock Split to Boost Share Price

Font: Financial Modeling Prep  • Apr 27, 2026

• Immunic, Inc. (NASDAQ: IMUX) executed a 1-for-10 reverse stock split on April 27, 2026, a strategic move for the biotechnology company.
• This corporate action significantly reduced the number of outstanding shares from approximately 136 million to about 13.6 million, aiming to increase the stock's price per share and fulfill contractual obligations.
• Following the split, Immunic's stock is priced at $9.76 per share, contributing to a market capitalization of approximately $96.32 million.

Immunic, Inc. (NASDAQ: IMUX) is a late-stage biotechnology company focused on developing new therapies. On April 27, 2026, the company performed a reverse stock split. This strategic corporate action reduces a company's number of outstanding shares to increase the price per share.

Immunic implemented a 1-for-10 reverse stock split. This means for every ten shares an investor owned, they now own one share. The company took this step to meet contractual obligations from a recent securities agreement. The decision was approved by its stockholders in a special meeting on April 14, 2026.

As a result of the split, the number of outstanding shares decreased from approximately 136 million to about 13.6 million. As highlighted by PR Newswire, the stock continues to trade on the Nasdaq Capital Market under the same "IMUX" symbol but on a split-adjusted basis.

Following the split, the stock price is $9.76 per share, marking an increase of 10.90%, or $0.96 for the day. The stock's daily trading range is between a low of $8.50 and a high of $10.30, with a trading volume of about 290,162 shares for the day.

Over the past year, Immunic's stock price has fluctuated between $5.06 and $15.10. The company has a market capitalization of approximately $96.32 million. Market capitalization is the total value of a company's shares, found by multiplying the share price by the number of outstanding shares.